EndoCells General Information
Developer of a novel proprietary pancreatic beta islet cell immortalization technology intended to focus on the generation and development of human endocrine cell lines. The company's technology platform allows the generation and development of human endocrine cell lines for drug screening and cell transplantation therapy of Type 1 diabetes, providing laboratories and industries with human beta cell lines for research, drug discovery, development and cell therapy.
Want to dig into this profile?
We’ll help you find what you need
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog »
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »